The immunotherapy developer, which is exploits Yale University research and counts Eli Lilly, Pfizer, Taiho and Ping An as investors, floated in the middle of its range after raising $160m in venture funding.

NextCure, a US-based immuno-oncology drug developer based on research at Yale University, has secured $75m in its initial public offering. The offering consisted of 5 million shares on the Nasdaq Global Select Market priced at $15 each, in the middle of its $14 to $16 range. NextCure is working on immunomedicines that will treat diseases…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.